The University of Southampton
University of Southampton Institutional Repository

Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests

Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests
Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a two-stage technique in which a CD34+ selection is followed by a tumour specific depletion stage using a B cell or breast cancer specific antibody panel. Initial small-scale selections on 11 patients with NHL and breast cancer showed that cell loss was greatest following the CD34+ selection with a median yield of 38.8 per cent (range 17. 2-56.4 per cent). The addition of the depletion stage resulted in a minimal loss of CD34+ cells with a yield for this step of 94.2 per cent (range 77.5-99.3 per cent). Clinical scale selections were performed on seven patients with CLL and a median of 2.8x10(6)/kg CD34+ cells (range 1.5-6.1x10(6)/kg) were collected. Cell recovery was 53.3 per cent following CD34+ selection and 76.9 per cent following the tumour specific depletion stage, resulting in a final product containing a median of 1.0x10(6)/kg CD34+ cells (range 0. 55-2.0x10(6)/kg). All unmanipulated harvests were heavily contaminated with tumour cells (median contamination 10.2 per cent, range 2.0-83.1 per cent) as measured by flow cytometry and a median 4.7 log (range 3-5 log) tumour cell purge was produced following two-stage selection. Six of the patients have received cells manipulated in this way with median engraftment times of neutrophils>0.5x10(9)/l=16 days (range 13-20 days) and platelets>20x10(9)/l=16.5 days (range 11-42 days). At a median follow-up of 25 months, these transplanted patients remain well and in molecular complete remission.
0278-0232
111-120
Davies, F. E.
b8c3d043-0c0c-4386-a5a7-be0ce86f71a4
Rawstron, A. C.
d0d0c6c7-f023-4dfc-9710-f02fa9378f81
Pratt, G.
a63c4fbf-4124-49d8-8b9f-cc722cc26e5c
Coupe, R.
9acd5991-1e41-470c-bd9a-5cea1271e113
Clarke, D.
43ade935-05d5-44ec-833b-313a246e7a37
Lubenko, A.
b272d1b7-7920-4d85-9bf7-d59ac6e10924
Short, K.
5ba61192-8f2d-4f43-917a-c1b2d097d1fb
Perren, T. J.
003bb719-be3f-4df3-9b88-d43253010630
Selby, P. J.
72d562a6-a9ec-45c6-bff8-f4defa60de68
Maclennan, S.
0db6ce5f-7734-4d74-b40d-0bd504feaccb
Major, K.
c6edb3a0-d6f6-4fe1-8ca9-d187366f8287
Woodhead, V.
3261e54d-7291-4bca-8879-b88cd843eda8
Robinson, F.
565cbab6-817d-4cfb-90df-a86905a6afea
Child, J. A.
9ca05a85-6e86-40b0-83e7-2c2afe5c20f5
Smith, G. M.
16f44588-dc46-443f-b23f-c6aaf872e220
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Morgan, G. J.
2eacfa78-f9fd-4216-9c50-04a3809ecd9e
Davies, F. E.
b8c3d043-0c0c-4386-a5a7-be0ce86f71a4
Rawstron, A. C.
d0d0c6c7-f023-4dfc-9710-f02fa9378f81
Pratt, G.
a63c4fbf-4124-49d8-8b9f-cc722cc26e5c
Coupe, R.
9acd5991-1e41-470c-bd9a-5cea1271e113
Clarke, D.
43ade935-05d5-44ec-833b-313a246e7a37
Lubenko, A.
b272d1b7-7920-4d85-9bf7-d59ac6e10924
Short, K.
5ba61192-8f2d-4f43-917a-c1b2d097d1fb
Perren, T. J.
003bb719-be3f-4df3-9b88-d43253010630
Selby, P. J.
72d562a6-a9ec-45c6-bff8-f4defa60de68
Maclennan, S.
0db6ce5f-7734-4d74-b40d-0bd504feaccb
Major, K.
c6edb3a0-d6f6-4fe1-8ca9-d187366f8287
Woodhead, V.
3261e54d-7291-4bca-8879-b88cd843eda8
Robinson, F.
565cbab6-817d-4cfb-90df-a86905a6afea
Child, J. A.
9ca05a85-6e86-40b0-83e7-2c2afe5c20f5
Smith, G. M.
16f44588-dc46-443f-b23f-c6aaf872e220
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Morgan, G. J.
2eacfa78-f9fd-4216-9c50-04a3809ecd9e

Davies, F. E., Rawstron, A. C., Pratt, G., Coupe, R., Clarke, D., Lubenko, A., Short, K., Perren, T. J., Selby, P. J., Maclennan, S., Major, K., Woodhead, V., Robinson, F., Child, J. A., Smith, G. M., Johnson, Peter W.M. and Morgan, G. J. (2000) Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests. Hematological Oncology, 18 (3), 111-120. (doi:10.1002/1099-1069(200009)18:3<111::AID-HON657>3.0.CO;2-#).

Record type: Article

Abstract

Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a two-stage technique in which a CD34+ selection is followed by a tumour specific depletion stage using a B cell or breast cancer specific antibody panel. Initial small-scale selections on 11 patients with NHL and breast cancer showed that cell loss was greatest following the CD34+ selection with a median yield of 38.8 per cent (range 17. 2-56.4 per cent). The addition of the depletion stage resulted in a minimal loss of CD34+ cells with a yield for this step of 94.2 per cent (range 77.5-99.3 per cent). Clinical scale selections were performed on seven patients with CLL and a median of 2.8x10(6)/kg CD34+ cells (range 1.5-6.1x10(6)/kg) were collected. Cell recovery was 53.3 per cent following CD34+ selection and 76.9 per cent following the tumour specific depletion stage, resulting in a final product containing a median of 1.0x10(6)/kg CD34+ cells (range 0. 55-2.0x10(6)/kg). All unmanipulated harvests were heavily contaminated with tumour cells (median contamination 10.2 per cent, range 2.0-83.1 per cent) as measured by flow cytometry and a median 4.7 log (range 3-5 log) tumour cell purge was produced following two-stage selection. Six of the patients have received cells manipulated in this way with median engraftment times of neutrophils>0.5x10(9)/l=16 days (range 13-20 days) and platelets>20x10(9)/l=16.5 days (range 11-42 days). At a median follow-up of 25 months, these transplanted patients remain well and in molecular complete remission.

This record has no associated files available for download.

More information

Published date: September 2000

Identifiers

Local EPrints ID: 157831
URI: http://eprints.soton.ac.uk/id/eprint/157831
ISSN: 0278-0232
PURE UUID: ba44c37e-b30a-4408-9b86-e3e86afc4b63
ORCID for Peter W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 16 Jun 2010 13:16
Last modified: 14 Mar 2024 02:41

Export record

Altmetrics

Contributors

Author: F. E. Davies
Author: A. C. Rawstron
Author: G. Pratt
Author: R. Coupe
Author: D. Clarke
Author: A. Lubenko
Author: K. Short
Author: T. J. Perren
Author: P. J. Selby
Author: S. Maclennan
Author: K. Major
Author: V. Woodhead
Author: F. Robinson
Author: J. A. Child
Author: G. M. Smith
Author: G. J. Morgan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×